Cosmos Health Inc (COSM)

Over the past six months, Cosmos Health Inc.'s stock price has decreased significantly. Key events impacting the stock include Nasdaq compliance issues, strategic updates and guidance, acquisition activities with a Letter of Intent to acquire a pharmacy distribution network in Greece, digital asset investments with the purchase of Bitcoin, U.S. expansion with the launch of its Sky Premium Life food supplements brand, and leadership appointments with Dr. Dimitrios Iliopoulos joining the Advisory Board.

Demand for Cosmos Health's pharmaceutical and nutraceutical offerings is likely influenced by seasonal trends. Nutraceutical demand surges in autumn and winter for immune support supplements, in January for fitness supplements, in summer for hydration supplements, and in spring for allergy supplements. Pharmaceutical demand rises in colder months for flu medications and in spring for allergy medications.

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group operating in the Healthcare sector, primarily in Medical Distribution, with activities in pharmaceutical manufacturing, nutraceuticals, healthcare services, and digital assets. The company manufactures, distributes, researches, develops, and provides digital health activities. Its products include nutraceutical lines like Sky Premium Life® and Mediterranation®, pharmaceutical brands like bio-bebe®, C-Sept®, and C-Scrub®, branded generics, OTC medications, food supplements, cosmetics, biocides, and medical devices. Cosmos Health also offers telehealth services through ZipDoctor, Inc. Its subsidiary, Cana Laboratories S.A., manufactures pharmaceuticals within the European Union.

Cosmos Health has a global distribution platform with operations and expansion efforts across Europe, Asia, and North America. The company has manufacturing and distribution operations in Greece and the United Kingdom, with offices and distribution centers in Thessaloniki and Athens, Greece, and Harlow, UK. Its telehealth and nutraceutical activities are also present in the United States, with U.S. market entry for its Sky Premium Life brand and the acquisition of ZipDoctor in Texas.

In the past year, Cosmos Health's brand reputation has been influenced by positive operational achievements and challenges reflected in its stock performance. Positive developments include record revenue and gross profit in Q3 2025, expansion into the U.S. market with the Sky Premium Life brand, and expansion of its C-Scrub product into major UK retailers. Challenges include a significant decline in the company's stock price and Nasdaq non-compliance notices.

Cosmos Health Inc. has a notable ownership structure with both institutional and individual investors. As of March 27, 2026, 24 institutional owners and shareholders held 12.61% of the company's stock. Major institutional owners include Renaissance Technologies Llc, BlackRock, Inc., and Vanguard Group Inc. Individually, CEO Grigorios Siokas holds approximately 19.86% of the company's shares as of November 2025, and has consistently increased his ownership throughout 2025.